Healthcare Industry News: BIOTRONIK
News Release - May 11, 2010
BIOTRONIK, Inc. Names Pat Horan VP of Corporate SalesCorporate Sales Executive Further Strengthens the Capabilities of the Fastest Growing Cardiac Rhythm Management Company in the U.S.
LAKE OSWEGO, Ore.--(HSMN NewsFeed)--BIOTRONIK, Inc., announced that effective May 14, 2010, Patrick L. Horan has accepted the position of Vice President of Corporate Sales for U.S. Operations. Mr. Horan will provide leadership for sales strategy with Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs), key regional and national healthcare providers and overall U.S. pricing/contracting strategy. The addition of Mr. Horan will help BIOTRONIK further accelerate the company’s already impressive growth trend relative to competitors in the Cardiac Rhythm Management (CRM) market.
Jake Langer, President of BIOTRONIK, Inc. adds, “We are extremely pleased to have Pat join BIOTRONIK, Inc., and are proud to have yet another highly capable and experienced contributor join our leadership team. This is the right time to add a leader with Pat’s capabilities to the strategic leadership group, and we expect the synergies to be readily apparent. Since he and Dan worked closely together in previous roles, the impact of this reunited team should be immediate.”
Mr. Horan adds, “BIOTRONIK provides an ideal way to re-enter this competitive market. Joining a team that has such a long-standing track record for product reliability was critical in this decision. I’m excited to see this reliability is being recognized and that so many talented industry professionals are being attracted to this growing organization.”
Mr. Horan is a 25-year veteran in the healthcare field and a highly successful leader in the CRM industry for more than 12 years as Senior Director of Operations Development and other Corporate Sales roles at Medtronic. Prior to this he held positions of increasing responsibility with Chiron Vision, Medtronic Neurological and Johnson & Johnson.
BIOTRONIK, Inc. is well positioned to take advantage of current uncertainties in the U.S. market. The company is unique in its ability to grow in spite of broader industry trends toward flat or declining revenue driven by concerns over product performance and increasing pressures exerted by proposed healthcare reform. “We’re prepared to take advantage of these opportunities. Private ownership allows BIOTRONIK to remain steadfastly focused on the core tenets of success in the CRM market. Delivering reliable products of uncompromising quality to physicians and the patients they serve is BIOTRONIK’s singular goal,” said Mr. Schlewitz. “Our controlled growth strategies enable us to make decisions that directly address the rapid changes that our industry is experiencing. Adding Pat’s capabilities now helps us continue to take market share in the U.S. at a time when publicly held companies are being forced to make decisions about resource allocation.”
As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 5,000 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.